March 8, 2024 Rare Neurodegenerative Disease Efforts Under the ACT for ALS In this webinar from The Critical Path Institute’s Rare and Orphan Disease Program CP-RND consortium, members discuss...
January 30, 2024 Webinar Recording: TRxA 2024 Funding Opportunities TRxA’s focus is translating early-stage novel therapeutics into Investigational New Drug (IND) supporting data packages that...
January 16, 2024 C-Path weighs in on key topics to advance Real-World Data and Artificial Intelligence in Rare Diseases Vice President, Cécile Ollivier, serves on a panel of distinguished experts in the EJP RD-EFPIA Joint Advanced Webinar on...
December 8, 2023 Understanding the Role of Patient Data in Drug Development Panel within a session titled “Understanding the role of patient data in drug development” at the 2023 International...
November 16, 2023 C-Path’s Translational Therapeutics Accelerator: A Unique Solution to Successfully Bridge the Valley of Death in Academic Drug Discovery and Development
August 9, 2023 C-Path’s Duchenne Regulatory Science Consortium and Duchenne Data Foundation Announce Collaboration to Advance Solutions for Duchenne Muscular Dystrophy TUCSON, Ariz. and VEENENDAAL, Netherlands, August 9, 2023 — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Con
July 6, 2023 Worldwide collaborative framework for optimizing new Parkinson’s treatment trials with patient centric outcome measures
May 3, 2023 Brief TRxA Overview – 15:48 In this video, TRxA Executive Director Maaike Everts and Associate Director Michelle Morgan give viewers a short overview of the C